A Phase 3 Efficacy Study of AGN-190584 in Participants With Presbyopia
Status:
Completed
Trial end date:
2020-09-10
Target enrollment:
Participant gender:
Summary
This clinical study will evaluate AGN-190584 in an expanded participant population to
establish efficacy, safety, and tolerability versus the vehicle-control when administered,
over a 30-day study intervention period, once daily bilaterally in participants with
presbyopia.